Frontlight ResearchEarly access
Trial site
University of California, San Francisco | HDFCCC - Hematopoietic Malignancies
- 3running trials
- 2closed trials
The trials here
What the 5 trials at this site are about, from their registry records.
- Conditions
- Bladder cancer3 trials
- Gastric and oesophageal cancer3 trials
- Cervical cancer2 trials
- Lung cancer2 trials
- Ovarian cancer2 trials
- Triple-negative breast cancer2 trials
- Colorectal cancer1 trial
- Diffuse large B-cell lymphoma1 trial
- Endometrial cancer1 trial
- Head and neck cancer1 trial
- Melanoma1 trial
- Metastatic breast cancer1 trial
- and 1 more
- Phase
- Phase 12 trials
- Phase 22 trials
- Phase 31 trial
- Status
- Active, not recruiting2 trials
- Terminated2 trials
- Recruiting1 trial
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer3 trials
- Seagen Inc.2 trials
Running trials
Active, not recruiting
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Active, not recruiting
Recruiting
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Bladder cancer1 recruiting
Closed trials
Site data: ClinicalTrials.govUpdated 12 Nov 2026